WO2013040212A3 - Unique transcriptional signatures in the blood of clinical responders - Google Patents

Unique transcriptional signatures in the blood of clinical responders Download PDF

Info

Publication number
WO2013040212A3
WO2013040212A3 PCT/US2012/055168 US2012055168W WO2013040212A3 WO 2013040212 A3 WO2013040212 A3 WO 2013040212A3 US 2012055168 W US2012055168 W US 2012055168W WO 2013040212 A3 WO2013040212 A3 WO 2013040212A3
Authority
WO
WIPO (PCT)
Prior art keywords
blood
transcriptional signatures
clinical responders
unique transcriptional
unique
Prior art date
Application number
PCT/US2012/055168
Other languages
French (fr)
Other versions
WO2013040212A2 (en
Inventor
Anna Karolina Palucka
Jose ROSELLO-URGELL
Jacques F. Banchereau
Joseph Fay
Damien Chaussabel
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of WO2013040212A2 publication Critical patent/WO2013040212A2/en
Publication of WO2013040212A3 publication Critical patent/WO2013040212A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A method for using the blood transcriptional profile of patients with stage IV melanoma to generate networks associated with the possibility of prolonged survival and networks associated with clinical responses to dendritic cell (DC) vaccination as measured by tumor regression are disclosed herein.
PCT/US2012/055168 2011-09-13 2012-09-13 Unique transcriptional signatures in the blood of clinical responders WO2013040212A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161533932P 2011-09-13 2011-09-13
US61/533,932 2011-09-13
US201213738545A 2012-09-13 2012-09-13
US13/738.545 2012-09-13

Publications (2)

Publication Number Publication Date
WO2013040212A2 WO2013040212A2 (en) 2013-03-21
WO2013040212A3 true WO2013040212A3 (en) 2013-10-31

Family

ID=47883968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/055168 WO2013040212A2 (en) 2011-09-13 2012-09-13 Unique transcriptional signatures in the blood of clinical responders

Country Status (1)

Country Link
WO (1) WO2013040212A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020187975A1 (en) * 2019-03-19 2020-09-24 SOTIO a.s. Patient selection for treatment with dendritic cell vaccination

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089521A2 (en) * 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy
US7640114B2 (en) * 2003-05-21 2009-12-29 The Wistar Institute Of Anatomy & Biology Method of diagnosis of cancer based on gene expression profiles in cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7640114B2 (en) * 2003-05-21 2009-12-29 The Wistar Institute Of Anatomy & Biology Method of diagnosis of cancer based on gene expression profiles in cells
WO2009089521A2 (en) * 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAJEWSKI ET AL.: "Association of gene expression profile in metastatic melanoma and survival to a dendritic cell-based vaccine", JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 15S, 2009 *
KIHARA ET AL.: "Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles", CANCER RESEARCH, vol. 61, 2001, pages 6474 - 6479, XP002960719 *
SAVLI ET AL.: "Gene network and canonical pathway analysis in prostate cancer: a microarray study", EXPERIMENTAL AND MOLECULAR MEDICINE, vol. 40, no. 2, April 2008 (2008-04-01), pages 176 - 185 *

Also Published As

Publication number Publication date
WO2013040212A2 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
MX353482B (en) METHODS FOR THE TREATMENT OF CANCER and INFLAMMATORY DISEASES USING CEREBLON AS A PREDICTOR.
RS60310B1 (en) Cyclic boronic acid ester derivatives, method for the preparation and therapeutic uses thereof
MY158992A (en) Forms of rifaximin and uses thereof
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
WO2012061835A3 (en) Apparatus and method for non-invasively detecting diseases that affect structural properties in biological tissues
HK1204537A1 (en) Method for determining glucose concentration in human blood
DK3311827T3 (en) NANOPARTICLES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF AS CARRIERS FOR AMPHIPATHIC OR HYDROPHOBIC MOLECULES IN THE MEDICAL FIELD, INCLUDING CANCER TREATMENT, AS WELL AS FOOD-RELATED COMPOUNDS
EP2758933A4 (en) Clinical analysis using electrodermal activity
EP2809153B8 (en) Apparatus for testing, assessment, and maintenance of harvested hearts for transplanting
RU2011134931A (en) STRAIN ENTEROCOCCUS USED FOR PREPARATION OF ACID-BEVERAGE DRINKS
EP2593012A4 (en) Blood glucose measurement method using blood glucose meter having step counter function
MX2012007898A (en) Methods of providing weight loss therapy in patients with major depression.
WO2011163566A3 (en) Methods of treating patients with immune-related diseases
PL2552401T3 (en) Use of a preparation obtained from an in vitro culture of dedifferentiated, non-elicited cells of the argania tree for treating skin ageing
FI20115670A0 (en) In vitro cardiovascular model
MX2012007970A (en) Process for the preparation of a biomass comprising plantaricin and uses thereof in medical field.
WO2012145399A3 (en) Methods of diagnosing cancer in a patient
EP2854872A4 (en) Method for sterilizing membrane comprising glucose oxidase and associated biosensor
WO2013040212A3 (en) Unique transcriptional signatures in the blood of clinical responders
EP2566879A4 (en) Method of functionalizing human red blood cells with antibody
MX351765B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease.
UA74336U (en) Method for diagnosing stenosis of vertebral artery
EP2675817B8 (en) Polytitanic acid esters and use thereof to produce implantable, optionally absorbable fibers
UA100317C2 (en) Method for the determination of human physiological status
TN2013000404A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 12832153

Country of ref document: EP

Kind code of ref document: A2